BiotechTube

Legalon® 140 mg

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-alcoholic Fatty Liver Disease (NAFLD)

Conditions

Non-alcoholic Fatty Liver Disease (NAFLD)

Trial Timeline

Aug 8, 2022 → Oct 31, 2024

NCT ID
NCT05051527

About Legalon® 140 mg

Legalon® 140 mg is a pre-clinical stage product being developed by Viatris for Non-alcoholic Fatty Liver Disease (NAFLD). The current trial status is completed. This product is registered under clinical trial identifier NCT05051527. Target conditions include Non-alcoholic Fatty Liver Disease (NAFLD).

Hype Score Breakdown

Clinical
5
Activity
2
Company
7
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT05051527Pre-clinicalCompleted

Competing Products

20 competing products in Non-alcoholic Fatty Liver Disease (NAFLD)

See all competitors
ProductCompanyStageHype Score
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
GODEX + PlaceboCelltrionPhase 3
77
ASP9831 + PlaceboAstellas PharmaPhase 2
52
AZD9550 + AZD9550 + PlaceboAstraZenecaPhase 1
33
AZD2693AstraZenecaPhase 1
33
placebo + Omega-3 carboxylic acids + Dapagliflozin + PlaceboAstraZenecaPhase 2
52
AZD4831AstraZenecaPhase 2
52
AZ compoundAstraZenecaPhase 2
52
cotadutide solution for injectionAstraZenecaPhase 1
33
Cotadutide + Cotadutide-placebo + Moxifloxacin + Moxifloxacin-placeboAstraZenecaPhase 1
33
AZD4076 + PlaceboAstraZenecaPhase 1
33
Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + PlaceboAstraZenecaPhase 2
52
Cotadutide + PlaceboAstraZenecaPhase 2
52
AZD7503 InterventionAstraZenecaPhase 1
33
Efinopegdutide + Semaglutide + PlaceboMerckPhase 2
52
MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochlorideMerckPhase 1
33
EfinopegdutideMerckPhase 1
33
LIK066 + PlaceboNovartisPhase 2
52
Tropifexor (LJN452) + Cenicriviroc (CVC)NovartisPhase 2
52
LYS006 + TropifexorNovartisPhase 2
52

Other Products from Viatris

Revefenacin + Tiotropium + Revefenacin Placebo + Tiotropium PlaceboApproved
82
PregabalinApproved
82
Imiquimod + DiclofenacApproved
82
gabapentin 600 mg + gabapentin 1200 mg + gabapentin 1800 mg + diazepam 20 mgApproved
82
Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsApproved
82